279 related articles for article (PubMed ID: 21185078)
21. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Goldberg SL
Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
[TBL] [Abstract][Full Text] [Related]
22. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
[TBL] [Abstract][Full Text] [Related]
23. Iron chelation therapy in MDS: what have we learnt recently?
Schmid M
Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
[TBL] [Abstract][Full Text] [Related]
24. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
[TBL] [Abstract][Full Text] [Related]
25. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
[TBL] [Abstract][Full Text] [Related]
26. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
27. Iron chelation therapy in myelodysplastic syndromes.
Fausel CA
Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S10-4; quiz S16. PubMed ID: 20332500
[TBL] [Abstract][Full Text] [Related]
28. An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.
Breccia M; Voso MT; Aloe Spiriti MA; Fenu S; Maurillo L; Buccisano F; Tafuri A; Alimena G
Ann Hematol; 2015 May; 94(5):771-7. PubMed ID: 25743685
[TBL] [Abstract][Full Text] [Related]
29. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.
Efficace F; Santini V; La Nasa G; Cottone F; Finelli C; Borin L; Quaresmini G; Di Tucci AA; Volpe A; Cilloni D; Quarta G; Sanpaolo G; Rivellini F; Salvi F; Molteni A; Voso MT; Alimena G; Fenu S; Mandelli F; Angelucci E
BMJ Support Palliat Care; 2016 Mar; 6(1):80-8. PubMed ID: 25204541
[TBL] [Abstract][Full Text] [Related]
31. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.
List AF; Baer MR; Steensma DP; Raza A; Esposito J; Martinez-Lopez N; Paley C; Feigert J; Besa E
J Clin Oncol; 2012 Jun; 30(17):2134-9. PubMed ID: 22547607
[TBL] [Abstract][Full Text] [Related]
32. CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
Bruch HR; Dencausse Y; Heßling J; Michl G; Schlag R; Skorupa A; Schneider-Schranz C; Wolf S; Schulte C; Tesch H
Oncol Res Treat; 2016; 39(7-8):424-31. PubMed ID: 27486873
[TBL] [Abstract][Full Text] [Related]
33. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
Ohyashiki JH; Kobayashi C; Hamamura R; Okabe S; Tauchi T; Ohyashiki K
Cancer Sci; 2009 May; 100(5):970-7. PubMed ID: 19298223
[TBL] [Abstract][Full Text] [Related]
34. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
[TBL] [Abstract][Full Text] [Related]
35. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.
Wimazal F; Nösslinger T; Baumgartner C; Sperr WR; Pfeilstöcker M; Valent P
Eur J Clin Invest; 2009 May; 39(5):406-11. PubMed ID: 19320908
[TBL] [Abstract][Full Text] [Related]
36. Delineating parameters of iron overload in MDS patients treated with deferasirox.
Leitch HA
Leuk Res; 2010 Dec; 34(12):1556-7. PubMed ID: 20719382
[No Abstract] [Full Text] [Related]
37. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
38. Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Breccia M; Finsinger P; Loglisci G; Federico V; Santopietro M; Colafigli G; Petrucci L; Salaroli A; Serrao A; Latagliata R; Alimena G
Ann Hematol; 2012 Sep; 91(9):1345-9. PubMed ID: 22569854
[TBL] [Abstract][Full Text] [Related]
39. Iron chelation therapy for patients with myelodysplastic syndrome.
Yeh SP; Yang YS; Yao CY; Peng CT
Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
[TBL] [Abstract][Full Text] [Related]
40. Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements.
Capalbo S; Spinosa G; Franzese MG; Palumbo G
Acta Haematol; 2009; 121(1):19-20. PubMed ID: 19287132
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
